Creating systemic oral transmucosal drug delivery strategies: Case study of APL-130277

Anthony Giovinazzo
Cynapsus Therapeutics, Inc.
Nathan Bryson
Cynapsus Therapeutics, Inc.
Timothy Tankosic
Aqua Partners LLC

DOI:https://doi.org/10.5912/jcb556

Abstract:

This article addresses the strategic application of systemic oral transmucosal* (i.e., sublingual and buccal) drug delivery. Circumvention of first-pass hepatic metabolism in the gut, rapid onset of action, easy access via the oral cavity, easy administration for patients with dysphagia and a high level of patient acceptance are the principal advantages of the oral transmucosal route. Key clinical and commercial strategies driving the development of oral transmucosal formulations are addressed. A case study of Cynapsus Therapeutics' APL-130277, a sublingual apomorphine formulation in clinical development for Parkinson's disease exemplifies the scientific, clinical and commercial considerations for systemic oral transmucosal drug delivery.

*Note: In this article, oral transmucosal delivery refers to systemic drug delivery through the sublingual or buccal mucosa. Local delivery to the oral mucosa is not included.

Keywords:sublingual ,oral transmucosal ,drug delivery ,apomorphine ,Parkinson's ,en ,